Hubei Biocause Pharmaceutical Co., Ltd. operates in the Life insurance sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hubei Biocause Pharmaceutical Co., Ltd. with three other
insurance companies in Asia:
Korean Reinsurance Company
of South Korea
sales of 9.01 trillion Korean Won [US$8.00 billion]
China Life Insurance Company Limited
(268.23 billion Taiwanese Dollars [US$8.70 billion]
of which 100%
was Insurance & Related Activities), and
Mercuries & Associates Investment Ltd
based in Taiwan
(215.56 billion Taiwanese Dollars [US$6.99 billion]
of which 86%
was Life Insurance).
Sales increased substantially in 2017:
Hubei Biocause Pharmaceutical Co., Ltd. reported sales of 53.41 billion Chinese Renmimbi (US$7.90 billion)
December of 2017.
increase of 214.3%
versus 2016, when the company's sales were 16.99 billion Chinese Renmimbi.
Sales of Insurance saw an increase
408.4% in 2017, from
9.23 billion Chinese Renmimbi to 46.91 billion Chinese Renmimbi.